锕锕锕锕锕锕～再深点+在线观看,痛痛痛痛痛痛疼疼色板推特,天天碰天天爱天天摸,成人18毛片女人

您好，歡迎來(lái)到上海士研管理咨詢有限公司
產(chǎn)業(yè)峰會(huì) 演講局 專(zhuān)家智庫(kù)服務(wù) 峰會(huì)活動(dòng)服務(wù) 整合營(yíng)銷(xiāo)服務(wù)
  • 產(chǎn)業(yè)峰會(huì)：
    以專(zhuān)業(yè)團(tuán)隊(duì)對(duì)產(chǎn)業(yè)和市場(chǎng)客觀詳實(shí)地調(diào)研為前提，擁有戰(zhàn)略性、系統(tǒng)性、全球性的基因，匯集了領(lǐng)導(dǎo)者關(guān)注的熱點(diǎn)話題與領(lǐng)袖代表，為您提供“一站式”的對(duì)話、分享、社交平臺(tái)!
  • 演講局：
    致力于為全球企業(yè)和機(jī)構(gòu)提供主題演講家、高管大師班、董事會(huì)顧問(wèn)，每項(xiàng)服務(wù)都提供了一種更深入、更具互動(dòng)性的體驗(yàn)，尤其是針對(duì)較小的精選受眾和關(guān)鍵個(gè)人。我們擁有最具影響力的商業(yè)領(lǐng)袖和頂級(jí)專(zhuān)家的資源，他們是各自領(lǐng)域的最杰出的代表。我們的團(tuán)隊(duì)由經(jīng)驗(yàn)豐富的演講和活動(dòng)經(jīng)理組成，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
  • 專(zhuān)家智庫(kù)服務(wù)：
    中國(guó)領(lǐng)先的行業(yè)專(zhuān)家知識(shí)信息服務(wù)供應(yīng)商，為需要專(zhuān)業(yè)洞見(jiàn)的商業(yè)決策者匹配具有一手經(jīng)驗(yàn)的行業(yè)專(zhuān)家，助力他們以更加明確的目標(biāo)和堅(jiān)定的信心做出決策。我們有60萬(wàn)余名專(zhuān)家顧問(wèn)遍布二十多個(gè)行業(yè)，而且每天還在增加！
  • 峰會(huì)活動(dòng)服務(wù)：
    致力于成為全球最專(zhuān)業(yè)的產(chǎn)業(yè)峰會(huì)活動(dòng)提供商，為企業(yè)和機(jī)構(gòu)的產(chǎn)業(yè)性峰會(huì)活動(dòng)提供一站式專(zhuān)業(yè)服務(wù)，包括調(diào)研策劃、定制邀請(qǐng)、營(yíng)銷(xiāo)推廣、運(yùn)營(yíng)組織、項(xiàng)目管理、直播與數(shù)字化會(huì)議等，每項(xiàng)服務(wù)都由經(jīng)驗(yàn)豐富的專(zhuān)業(yè)團(tuán)隊(duì)匹配長(zhǎng)期沉淀的產(chǎn)業(yè)資源予以卓越執(zhí)行，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
  • 整合營(yíng)銷(xiāo)服務(wù)：
    致力于成為全球領(lǐng)先的2B營(yíng)銷(xiāo)服務(wù)機(jī)構(gòu)，聚焦產(chǎn)業(yè)高端活動(dòng)、內(nèi)容、渠道的建設(shè)與沉淀，為客戶提供一站式整合營(yíng)銷(xiāo)解決方案，助力企業(yè)線上線下獲客與品牌筑造。我們深信專(zhuān)業(yè)團(tuán)隊(duì)匹配產(chǎn)業(yè)資源帶來(lái)卓越執(zhí)行，我們注重建立長(zhǎng)期而深入的伙伴關(guān)系。
會(huì)議贊助商
7
2022 - 03 - 08
點(diǎn)擊次數(shù):
燃石醫(yī)學(xué)（納斯達(dá)克代碼：BNR）成立于2014年，公司使命為“用科學(xué)守護(hù)生命之光”，專(zhuān)注于為腫瘤精準(zhǔn)醫(yī)療提供具有臨床價(jià)值的二代基因測(cè)序（NGS）。公司業(yè)務(wù)及研發(fā)方向主要覆蓋：1）基于NGS的腫瘤患病人群檢測(cè)，6年間，燃石累計(jì)檢測(cè)樣本超過(guò)25萬(wàn)例，在中國(guó)擁有最高的市場(chǎng)份額；2）基于NGS的癌癥早檢，目前已經(jīng)進(jìn)入臨床驗(yàn)證階段。燃石醫(yī)學(xué)于2018年7月獲國(guó)家藥品監(jiān)督管理局（NMPA）頒發(fā)的中國(guó)腫瘤NGS檢測(cè)試劑盒第一證，在體外診斷領(lǐng)域具有里程碑式意義。實(shí)驗(yàn)室獲得廣東省臨檢中心頒發(fā)的 “高通量測(cè)序?qū)嶒?yàn)室”技術(shù)審核，以及得美國(guó)CLIA和CAP實(shí)驗(yàn)室質(zhì)量體系資質(zhì)認(rèn)證。公司將繼續(xù)致力于開(kāi)發(fā)創(chuàng)新可靠的NGS檢測(cè)產(chǎn)品，推動(dòng)腫瘤精準(zhǔn)醫(yī)療領(lǐng)域的發(fā)展。 About Burning RockBurning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 250,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage. In July 2018, Burning Rock received the first approval for a tumor NGS kit by the National Medical Products Administration (NMPA), which is a significant milestone in the field of in vitro diagnosis in China. Burning Rock’s laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification. The company continues to be committed to the development of innovative and reliable NGS testing products and promoting the development of precision medicine in oncology.
8
2022 - 03 - 08
點(diǎn)擊次數(shù):
石家莊高新技術(shù)產(chǎn)業(yè)開(kāi)發(fā)區(qū)是1991年3月經(jīng)國(guó)務(wù)院批準(zhǔn)設(shè)立的首批國(guó)家級(jí)高新區(qū)之一，面積78平方公里，現(xiàn)已入駐各類(lèi)市場(chǎng)主體30000余家，科技型中小企業(yè)2665家，高新技術(shù)企業(yè)1022家。目前，已構(gòu)筑起以生物醫(yī)藥健康產(chǎn)業(yè)為主導(dǎo)，新一代信息技術(shù)、先進(jìn)裝備制造、現(xiàn)代服務(wù)業(yè)協(xié)同發(fā)展的'1+3'產(chǎn)業(yè)體系，在全國(guó)25家“生物醫(yī)藥創(chuàng)新型產(chǎn)業(yè)集群”中位列第1位，全國(guó)生物醫(yī)藥園區(qū)創(chuàng)新藥物潛力指數(shù)10強(qiáng)中位列第5位，全國(guó)生物醫(yī)藥園區(qū)50強(qiáng)中位列第7位。Shijiazhuang High-tech Industrial Development Zone is one of the first state-level high-tech zones approved by The State Council in March 1991. Covering an area of 78 square kilometers, it has now settled more than 30000 market entities,2665 small and medium-sized sci-tech enterprises and 1022 high-tech enterprises. At present, it has built a '1+3' industrial system dominated by biomedicine and health industry and accompanied by the development of the next-generation IT industry, advanced equipment manufacturing industry and modern service industry.It ranks 1st among the 25 'Biomedical innovative industrial clusters',5th among the top 10 biomedical parks of innovative medicine research and production and 7th among the top 50 national biomedical parks in China.
9
2022 - 03 - 08
點(diǎn)擊次數(shù):
長(zhǎng)沙通諾信息科技有限責(zé)任公司（簡(jiǎn)稱(chēng)“通諾信息”）成立于2017 年4 月10 日。專(zhuān)注于藥學(xué)和臨床研究信息化建設(shè)，致力為國(guó)內(nèi)外制藥企業(yè)、科研單位和政府機(jī)構(gòu)提供全面綜合的信息技術(shù)解決方案，助力醫(yī)藥行業(yè)信息化升級(jí)，推動(dòng)新藥研發(fā)進(jìn)程，保障患者用藥安全。通諾信息自主研發(fā)ILP（智慧實(shí)驗(yàn)室平臺(tái)）和ICP（智慧臨床研究平臺(tái)）兩大信息化平臺(tái)，為藥學(xué)與臨床研究提供整體解決方案。公司各系統(tǒng)已部署于國(guó)內(nèi)外近100家科研單位、制藥企業(yè)、CRO公司、臨床試驗(yàn)機(jī)構(gòu)和倫理委員會(huì)，支撐超過(guò)1000個(gè)項(xiàng)目和課題順利開(kāi)展，成功篩查及入組受試者超過(guò)2萬(wàn)人，管理試驗(yàn)樣本近50萬(wàn)，3項(xiàng)藥學(xué)研發(fā)項(xiàng)目通過(guò)國(guó)家局核查。 Changsha Tonoinfo Technology Co., Ltd. (hereinafter referred to as 'Tonoinfo') was established on April 10, 2017. Focusing on the informatization construction of pharmaceutical and clinical research, the company is committed to providing comprehensive information technology solutions for domestic and foreign pharmaceutical enterprises, scientific research institutions and government agencies, to help upgrade the informatization of the pharmaceutical industry, promote the process of new drug research and development, and ensure the safety of drug use for patients.Tonoinfo has independently developed two information platforms, ILP (Intelligent Laboratory Platform) and ICP (Intelligent Clinical Research Platform), to provide overall solutions for pharmaceutical and clinical research. The company's systems have been deployed in nearly 100 domestic and foreign scientific research institutions, pharmaceutical companies, CRO companies, clinical trial institutions and ethics committees, supporting the smooth development of more than 1,000 projects and topics, successful screening and inclusion of more than 20,000 subjects, the management of nearly 500,000 test samples, 3 pharmaceutical research and development projects passed the national inspection.
微信公眾號(hào)
領(lǐng)導(dǎo)者網(wǎng)絡(luò)APP
Copyright ?2005 - 2017上海士研管理咨詢有限公司
犀牛云提供企業(yè)云服務(wù)